Condition: Solid Tumors · Ovarian Cancer · Small Cell Lung Cancer · Sponsor: Heronova Pharmaceuticals
This study is a multicenter, open-label, cohort expansion Phase Ib/IIa trial designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of DC05F01 in patients with recurrent/refractory ovarian cancer and other advanced solid tumors.
This description comes directly from the study's public registry record.
Kang Ren · +86-13269683867 · renkang@dcpc.com
Always discuss trial participation with your own doctor first.
| The Fisrt Affiliated Hospital of Bengbu Medical University | Bengbu, Anhui, China | Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06873555